Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Champions Oncology (CSBR) Competitors

Champions Oncology logo

CSBR vs. TVGN, TCRX, STRO, MOLN, SOPH, GNFT, INBX, ZURA, EDIT, and SLDB

Should you be buying Champions Oncology stock or one of its competitors? The main competitors of Champions Oncology include Tevogen Bio (TVGN), TScan Therapeutics (TCRX), Sutro Biopharma (STRO), Molecular Partners (MOLN), SOPHiA GENETICS (SOPH), Genfit (GNFT), Inhibrx (INBX), Zura Bio (ZURA), Editas Medicine (EDIT), and Solid Biosciences (SLDB). These companies are all part of the "biological products, except diagnostic" industry.

Champions Oncology vs.

Tevogen Bio (NASDAQ:TVGN) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Tevogen Bio has higher earnings, but lower revenue than Champions Oncology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tevogen BioN/AN/A-$70KN/AN/A
Champions Oncology$50.15M1.17-$7.28M-$0.26-16.54

41.3% of Champions Oncology shares are held by institutional investors. 56.6% of Tevogen Bio shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Champions Oncology received 149 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 60.24% of users gave Champions Oncology an outperform vote.

CompanyUnderperformOutperform
Tevogen BioOutperform Votes
1
100.00%
Underperform Votes
No Votes
Champions OncologyOutperform Votes
150
60.24%
Underperform Votes
99
39.76%

Tevogen Bio has a net margin of 0.00% compared to Champions Oncology's net margin of -6.58%. Champions Oncology's return on equity of 0.00% beat Tevogen Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Tevogen BioN/A -387.78% 434.75%
Champions Oncology -6.58%N/A -12.80%

Tevogen Bio currently has a consensus price target of $4.20, suggesting a potential upside of 195.77%. Champions Oncology has a consensus price target of $6.00, suggesting a potential upside of 39.53%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tevogen Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Champions Oncology
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Tevogen Bio had 3 more articles in the media than Champions Oncology. MarketBeat recorded 4 mentions for Tevogen Bio and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.04 beat Tevogen Bio's score of -0.13 indicating that Champions Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tevogen Bio
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Champions Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tevogen Bio has a beta of -1.05, indicating that its stock price is 205% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Summary

Tevogen Bio beats Champions Oncology on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CSBR vs. The Competition

MetricChampions OncologyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$61.85M$2.93B$5.07B$8.89B
Dividend YieldN/A1.91%4.99%4.07%
P/E Ratio-16.5415.0083.5712.93
Price / Sales1.17280.711,220.3088.33
Price / CashN/A168.0739.4636.25
Price / Book-30.714.696.936.25
Net Income-$7.28M-$41.63M$119.12M$225.93M

Champions Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CSBR
Champions Oncology
4.1504 of 5 stars
$4.30
-5.5%
$6.00
+39.5%
-21.2%$61.85M$50.15M-16.54143Short Interest ↓
Positive News
TVGN
Tevogen Bio
3.2817 of 5 stars
$1.42
+4.4%
$4.20
+195.8%
N/A$232.08MN/A0.0017Gap Up
TCRX
TScan Therapeutics
2.9905 of 5 stars
$4.12
-2.1%
$12.00
+191.3%
-10.6%$223.02M$21.05M0.00100
STRO
Sutro Biopharma
4.5351 of 5 stars
$2.67
-1.1%
$12.14
+354.8%
-3.6%$222.64M$153.73M0.00240Analyst Forecast
Analyst Revision
MOLN
Molecular Partners
0.2312 of 5 stars
$5.20
-4.8%
$4.50
-13.5%
+19.8%$220.24M$7.84M0.00180
SOPH
SOPHiA GENETICS
1.4237 of 5 stars
$3.17
-3.1%
$6.50
+105.0%
-14.6%$213.78M$62.37M0.00520
GNFT
Genfit
1.4608 of 5 stars
$4.31
+1.2%
$13.00
+201.6%
+27.1%$212.95M$41.31M0.00120
INBX
Inhibrx
1.2884 of 5 stars
$14.04
-1.7%
N/A-36.9%$206.86M$1.63M0.00166
ZURA
Zura Bio
3.9055 of 5 stars
$2.90
-7.9%
$15.80
+444.8%
-35.1%$205.68MN/A0.003Analyst Forecast
EDIT
Editas Medicine
4.7809 of 5 stars
$2.41
-2.8%
$9.08
+276.9%
-77.8%$204.72M$78.12M-0.94230Short Interest ↓
SLDB
Solid Biosciences
3.3235 of 5 stars
$4.96
-2.9%
$15.14
+205.3%
+108.4%$204.17M$8.09M-1.63100

Related Companies and Tools


This page (NASDAQ:CSBR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners